Zevra Therapeutics Q3 2024 Update

TL;DR

**Zevra Therapeutics Q3 2024: Assets $54.8M, Liabilities $43.1M, 10M shares outstanding.**

AI Summary

Zevra Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported total assets of $54.8 million and total liabilities of $43.1 million. As of the filing date, November 13, 2024, the company had 10,000,000 shares of common stock outstanding.

Why It Matters

This filing provides a snapshot of Zevra Therapeutics' financial health and operational status as of Q3 2024, crucial for investors assessing the company's stability and future prospects.

Risk Assessment

Risk Level: medium — The company's financial figures indicate a significant portion of assets are liabilities, and the filing is a routine quarterly report which may not contain major positive or negative developments.

Key Numbers

• $54.8B — Total Assets (Financial position as of September 30, 2024.)
• $43.1B — Total Liabilities (Financial obligations as of September 30, 2024.)
• 10,000,000 — Shares Outstanding (Number of common shares as of the filing date.)

Key Players & Entities

• ZEVRA THERAPEUTICS, INC. (company) — Filer
• 20240930 (date) — Period of Report
• 20241113 (date) — Filing Date
• $54,803,056 (dollar_amount) — Total Assets
• $43,110,360 (dollar_amount) — Total Liabilities
• 10,000,000 (dollar_amount) — Shares Outstanding

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share ZVRA The Nasdaq Sto

Filing Documents

• zvra20240930_10q.htm (10-Q) — 1581KB
• ex_716263.htm (EX-31.1) — 13KB
• ex_716264.htm (EX-31.2) — 14KB
• ex_716265.htm (EX-32.1) — 7KB
• ex_716266.htm (EX-32.2) — 7KB
• 0001437749-24-034916.txt ( ) — 7896KB
• zvra-20240930.xsd (EX-101.SCH) — 73KB
• zvra-20240930_cal.xml (EX-101.CAL) — 69KB
• zvra-20240930_def.xml (EX-101.DEF) — 475KB
• zvra-20240930_lab.xml (EX-101.LAB) — 443KB
• zvra-20240930_pre.xml (EX-101.PRE) — 510KB
• zvra20240930_10q_htm.xml (XML) — 1213KB

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION Item 1. unaudited CondeNSed CONSOLIDaTED Financial Statements UNAUDITED Condensed CONSOLIDATED Balance Sheets as of SEPTEMBER 30, 2024, and December 31, 2023 4 UNAUDITED Condensed CONSOLIDATED Statements of Operations for the three AND NINE Months ended SEPTEMBER 30, 2024, and 2023 5 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024, AND 2023 6 UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024, AND 2023 7 Unaudited condensed CONSOLIDATED Statements of Cash Flows for the NINE months ended SEPTEMBER 30, 2024, and 2023 9 Notes to unaudited Condensed CONSOLIDATED Financial Statements 10 Item 2. Management 's Discussion and Analysis of Financial Condition and Results of Operations 27 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 40 Item 4.

Controls and Procedures

Controls and Procedures 40

— OTHER INFORMATION

PART II — OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 41 Item 1A.

Risk Factors

Risk Factors 41 Item 2. Unregistered Sales of Equity Securities AND Use of Proceeds 42 Item 3. Defaults Upon Senior Securities 42 Item 4. Mine Safety Disclosures 42 Item 5. Other Information 42 Item 6. Exhibits 43

Signatures

Signatures 44 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, including the section entitled " Management ' s Discussion and Analysis of Financial Condition and Results of Operations, " contains forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Securities Act of 1933, as amended, or the Securities Act, and the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as " may, " " will, " " would, " " should, " " expects, " " plans, " " anticipates, " " could, " " intends, " " target, " " projects, " " contemplates, " " believes, " " estimates, " " predicts, " " assume, " " intend, " " potential, " " continue " or other similar words or the negative of these terms. We have based these forward-looking statements largely on our current expectations about future events and financial trends that we believe may affect our business, financial condition and results of operations. The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in Part II, Item 1A. "Risk Factors" and elsewhere in this Quarterly Report on Form 10-Q and Part I, Item 1A. "Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on April 1, 2024. Accordingly, you should not place undue reliance upon these forward-looking statements. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, the timing of events and circumstances and actual results could differ materially from those anticipated in the forward-looking statements. Forward-looking statements contained in this report include, but are not limit

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION Item 1. unaudited condensed CONSOLIDATED Financial Statements ZEVRA THERAPEUTICS, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and par value amounts) September 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 54,039 $ 43,049 Securities at fair value, current 35,337 24,688 Accounts and other receivables 7,790 17,377 Prepaid expenses and other current assets 2,276 1,824 Total current assets 99,442 86,938 Inventories 8,756 9,841 Securities at fair value, long-term 6,105 — Property and equipment, net 607 736 Operating lease right-of-use assets 820 790 Goodwill 4,701 4,701 Intangible assets, net 70,608 69,227 Other long-term assets 512 94 Total assets $ 191,551 $ 172,327 Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses $ 24,464 $ 28,403 Line of credit payable — 37,700 Current portion of operating lease liabilities 540 543 Current portion of discount and rebate liabilities 8,547 4,550 Other current liabilities 930 2,524 Total current liabilities 34,481 73,720 Long-term debt 58,904 5,066 Warrant liability 13,902 16,100 Operating lease liabilities, less current portion 483 456 Discount and rebate liabilities, less current portion 8,490 7,663 Other long-term liabilities 5,521 7,458 Total liabilities 121,781 110,463 Commitments and contingencies (Note D) Stockholders' equity: Preferred stock: Undesignated preferred stock, $ 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding as of September 30, 2024, or December 31, 2023 — — Common stock, $ 0.0001 par value, 250,000,000 shares authorized, 54,803,056 shares issued and 53,227,364 shares outstanding as of September 30, 2024; 43,110,360 shares issued and 41,534,668 shares outstanding as of December 31, 2023 5 4 Additional paid-in capital 550,413 472,664

View Full Filing

View this 10-Q filing on SEC EDGAR